Literature DB >> 34686971

Subacute thyroiditis after SARS-CoV-2 vaccination: a report of two sisters and summary of the literature.

Sofia Chatzi1, Athina Karampela1, Chara Spiliopoulou2, Georgios Boutzios3.   

Abstract

Entities:  

Keywords:  SARS-CoV-2 vaccination; Subacute thyroiditis

Mesh:

Substances:

Year:  2021        PMID: 34686971      PMCID: PMC8536248          DOI: 10.1007/s42000-021-00332-z

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


× No keyword cloud information.
Subacute thyroiditis (SAT), an inflammatory disorder of the thyroid gland, is often self-limiting [1]. There are only a few cases in literature in which SAT is related to the SARS-CoV-2 vaccination [2]. Herein, we report the cases of two sisters presenting with SAT a few days after receiving the COVID-19 mRNA vaccine, and summarize the relevant data reported in the literature.

Case 1

A 35-year-old female, non-smoker, presented to the outpatient clinic due to acute neck pain radiating to the jaw and ear, fatigue, and rare palpitations. As regards her family history, her mother had been diagnosed with Hashimoto’s thyroiditis 20 years previously. The patient had tenderness on palpation over the thyroid area. She received the SARS-CoV-2 vaccine several days before the appearance of the symptoms (specifically, 12 days before she received the first dose). The patient’s biochemical parameters and thyroid functional tests are presented in Table 1. Thyroid sonography revealed increased gland dimensions with heterogeneous appearance and with hypoechogenic regions. The technetium pertechnetate (99mTcO4) thyroid scan showed low uptake from the thyroid parenchyma with irregular gland margins. Prednisolone treatment was initiated [3].
Table 1

Patient’s biochemical parameters and thyroid functional tests

Authors
Our casesTekin et alOyibo S.OIremli et alFranquemont et al
Case 1Case 2Case 1Case 2Case 3
Type of vaccine

SARS-CoV-2 mRNA

(Pfizer/BioNTech)

SARS-CoV-2 mRNA

(Pfizer/BioNTech)

SARS-CoV-2 Vaccine (Vero Cell), Inactivated (CoronaVac®, Sinovac Life Sciences, Beijing)Non Replicating Viral Vector (Oxford-AstraZeneca, UK)SARS-CoV-2 Vaccine (Vero Cell), Inactivated (CoronaVac®, Sinovac Life Sciences, Beijing)SARS-CoV-2 Vaccine (Vero Cell), Inactivated (CoronaVac®, Sinovac Life Sciences, Beijing)SARS-CoV-2 Vaccine (Vero Cell), Inactivated (CoronaVac®, Sinovac Life Sciences, Beijing)

SARS-CoV-2 mRNA

(Pfizer/BioNTech)

Time lag (vaccination to disease manifestation)12 d (after 1st dose)4 d (after 2nd dose)18 d (after 2nd dose)21d (after 1st dose)4d (after 2nd dose)4d (after 1st dose)7d (after 2nd dose)

5d

(after 1st dose)

Age35y.o32y.o67y.o55y.o35y.o34y.o37y.o42y.o
SymptomsNeck pain, fatigue, palpitationsNeck pain, fatigueFever, weight lose, neck painNeck pain, swelling,headache, sore throat, palpitations, generalized achesNeck pain, palpitationsNeck pain, fatigue, weight lossNeck painSore throat, palpitations
TSH↓↓↓↓ → ↓↓ → ↓↓
FT4 →  →  →  → 
Anti-TPONegativeNegativeNegativeNegativeNegativeNegativeNegativeNegative
Anti-TGNegativeNegativeNegative-NegativeNegativeNegativeNegative
TRABNegativeNegativeNegative-NegativeNegativeNegativeNegative
WBC →  → - →  →  →  → -
ESR754013456,653192562
CRP4981053,987100,562,4-
Type of therapyPrednisolonePrednisoloneIbuprofenIbuprofen, paracetamol, propranololMethylprednisoloneMethylprednisoloneNo treatmentPrednisone, propranolol

Abbreviations: TSH: → within n.v, ↓ 0.01–0.2 μIU/ml, ↓↓ <0.01 μIU/ml, FT4: →within n.v., ↑ increased, ↓ decreased, ESR n.v <20 mm/hr, CRP n.v. <5mg/L

Patient’s biochemical parameters and thyroid functional tests SARS-CoV-2 mRNA (Pfizer/BioNTech) SARS-CoV-2 mRNA (Pfizer/BioNTech) SARS-CoV-2 mRNA (Pfizer/BioNTech) 5d (after 1st dose) Abbreviations: TSH: → within n.v, ↓ 0.01–0.2 μIU/ml, ↓↓ <0.01 μIU/ml, FT4: →within n.v., ↑ increased, ↓ decreased, ESR n.v <20 mm/hr, CRP n.v. <5mg/L

Case 2

A 32-year-old female, sister of case 1, non-smoker, presented with neck pain radiating to the jaw and ear, and mild fatigue. She had had an endometritis infection 1 month earlier, which was treated with doxycycline and roxithromycin. The patient had tenderness on neck palpation. She had received the second dose of SARS-CoV-2 vaccine 4 days before the symptoms appeared. The patient’s biochemical parameters and thyroid functional tests are presented in Table 1. Thyroid sonography revealed increased gland dimensions with heterogeneous appearance and hypoechogenic regions. The 99mTcO4 scan showed low uptake from the thyroid parenchyma with irregular gland margins. Prednisolone treatment was initiated [3]. SAT has previously been described as a complication following administration of other vaccines, such as the influenza and hepatitis B vaccines, but there are only a small number of reports in the literature regarding SAT after SARS-CoV-2 vaccination. Iremli et al. describe three cases of female patients presenting with SAT a few days after receiving the inactivated SARS-CoV-2 vaccine (Coronavac) [4]. Oyibo S.O. reports a case of a 55-year-old female with SAT some days subsequent to administration of the adenovirus-vectored COVID-19 vaccine (Oxford-AstraZeneca) [5]. Tekin et al. describe the case of a 67-year-old male patient presenting with SAT several days after receiving the second dose of Coronavac [6]. Finally, only one case of SAT occurring following the mRNA SARS-COV-2 vaccine has been reported that concerned a 42-year-old female patient with SAT onset soon after administration of the Pfizer/BioNTech mRNA vaccine [7]. The exact pathogenetic mechanism underlying incidence of SAT as a complication following the SARS-CoV-2 vaccination is as yet unclear. Adjuvants in the vaccines or crosstalk between the coronavirus spike protein target and antigens from thyroid cells may cause inflammatory or autoimmune reaction. In our cases, the fact that SAT occurred in two sisters points to the potential role of genetic predisposition, which remains to be further investigated. We present these cases in order to raise awareness of the possible association between the SARS-CoV-2 vaccination and thyroid disorders, in particular, subacute thyroiditis, so that early recognition of the condition can lead to successful management.
  2 in total

1.  Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Post-vaccination ASIA Syndrome.

Authors:  Burçin Gönül İremli; Süleyman Nahit Şendur; Uğur Ünlütürk
Journal:  J Clin Endocrinol Metab       Date:  2021-05-27       Impact factor: 5.958

2.  Subacute Thyroiditis After Receiving the Adenovirus-Vectored Vaccine for Coronavirus Disease (COVID-19).

Authors:  Samson O Oyibo
Journal:  Cureus       Date:  2021-06-29
  2 in total
  12 in total

1.  Subacute thyroiditis after receiving the vaccine for COVID-19: a case report and literature review.

Authors:  Thanh Binh Vu; Dinh Toi Chu; Dinh Tuan Le; Thi Thuy Dieu Hoang; Philippe Gautret; Van Thuan Hoang
Journal:  Clin Exp Vaccine Res       Date:  2022-05-31

2.  Thyroid Inconveniences With Vaccination Against SARS-CoV-2: The Size of the Matter. A Systematic Review.

Authors:  Verdiana Caironi; Fabián Pitoia; Pierpaolo Trimboli
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-23       Impact factor: 6.055

3.  Evaluation of the diagnostic features and clinical course of COVID-19 vaccine-associated subacute thyroiditis.

Authors:  Hayri Bostan; Serdar Kayihan; Murat Calapkulu; Sema Hepsen; Umran Gul; Ilknur Ozturk Unsal; Muhammed Kizilgul; Muhammed Erkam Sencar; Erman Cakal; Bekir Ucan
Journal:  Hormones (Athens)       Date:  2022-06-16       Impact factor: 3.419

4.  Graves' Disease Following COVID-19 Vaccination.

Authors:  Gurdeep Singh; Timothy Howland
Journal:  Cureus       Date:  2022-04-23

Review 5.  The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine.

Authors:  Mihaela Popescu; Adina Ghemigian; Corina Maria Vasile; Andrei Costache; Mara Carsote; Alice Elena Ghenea
Journal:  Diagnostics (Basel)       Date:  2022-04-12

6.  Subacute thyroiditis during the COVID-19 pandemic: a prospective study.

Authors:  A B Bahçecioğlu; Z C Karahan; B I Aydoğan; I A Kalkan; A Azap; M F Erdoğan
Journal:  J Endocrinol Invest       Date:  2022-01-13       Impact factor: 5.467

7.  Recurring subacute thyroiditis after SARS-CoV-2 mRNA vaccine: A case report.

Authors:  Vasiliki Vasileiou; Stavroula A Paschou; Xakousti Tzamali; Marina Mitropoulou; Fotini Kanouta; Theodora Psaltopoulou; Georgia N Kassi
Journal:  Case Rep Womens Health       Date:  2021-12-28

Review 8.  Subacute Thyroiditis After Receiving the mRNA COVID-19 Vaccine (Moderna): The First Case Report and Literature Review in Korea.

Authors:  Min Jhon; Sun-Ho Lee; Tae-Hoon Oh; Ho-Cheol Kang
Journal:  J Korean Med Sci       Date:  2022-02-14       Impact factor: 2.153

Review 9.  Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence.

Authors:  A Jafarzadeh; M Nemati; S Jafarzadeh; P Nozari; S M J Mortazavi
Journal:  J Endocrinol Invest       Date:  2022-03-26       Impact factor: 5.467

10.  Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study.

Authors:  Stavroula A Paschou; Vangelis Karalis; Theodora Psaltopoulou; Vasiliki Vasileiou; Ioanna Charitaki; Tina Bagratuni; Vassiliki Ktena; Fotini Papandroulaki; Sentiljana Gumeni; Georgia N Kassi; Ioannis P Trougakos; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.